|
Market Closed -
Other stock markets
|
After hours 00:39:17 | |||
| 108.53 USD | +0.65% |
|
107.66 | -0.81% |
| 06-11 | Guggenheim Lifts Price Target on Incyte to $136 From $130, Maintains Buy Rating | MT |
| 06-11 | William O'Neil Initiates Incyte at Buy | MT |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Compared values
| Sector | Change | 5-day change | YTD change | 1-year change | 5-year change | Capi. | ST | MT | LT | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| INCYTE CORPORATION | Biopharmaceuticals | +0.65% | +6.01% | +9.88% | +56.79% | +31.42% | 21.68B |  |  | |
- Stock Market
- Stocks
- INCY Stock
- Charts Incyte Corporation
- Comparison Chart
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition